IP Library Granted Patent US 9,809,539
Granted Patent B2
US 9,809,539 · App. 14/636,736 · Granted Nov 7, 2017

Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

Inventors: Scott Grindrod (Rockville, MD); Mira Jung (Rockville, MD); Milton Brown (Rockville, MD); Anatoly Dritschilo (Rockville, MD)
Assignee: Shuttle Pharmaceuticals, LLC
C07D209/42A61K31/404A61K31/573A61K45/06A61N5/00C07D209/20C07D403/14A61N2005/1098
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,809,539
App. No.
14/636,736
Granted
Nov 7, 2017
Kind
B2
Abstract

Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.

Claims (12)

1. A compound of the formula:

for a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is selected from the group consisting of:

and the pharmaceutically acceptable salts thereof.

3. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical formulation, in unit dosage form, comprising a compound in an amount effective to inhibit histone deacetylase (HDAC) and activate ataxia telangiectasia mutated (ATM) in a patient in need thereof and at least one physiologically compatible carrier medium, wherein the compound is selected from the group consisting of

and the pharmaceutically acceptable salts thereof.

5. The pharmaceutical formulation of claim 4 , wherein the compound is selected from the group consisting of:

and the pharmaceutically acceptable salts thereof.

6. The pharmaceutical formulation of claim 4 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2015
From: GRINDROD, SCOTT; JUNG, MIRA; BROWN, MILTON; DRITSCHILO, ANATOLY
To: SHUTTLE PHARMACEUTICALS, LLC
Reel/Frame 036464/0350 →
Continuity (1)
Related Publication 20160257649A1 · Sep 8, 2016